Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01207115 · ClinicalTrials.gov registry record · Phase 2

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

A Phase 2 study, sponsored by AbbVie (prior sponsor, Abbott).

Completed
Registry status
Phase 2
Development phase
322
Enrollment target

NCT01207115 is a Phase 2 study that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 322 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01207115, a Phase 2 study, has completed, sponsored by AbbVie (prior sponsor, Abbott).

COMPLETED
Registry status
Phase 2
Development phase
322 participants
Enrollment target

Study Summary

To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.

Interventions

  • DRUG Placebo
  • DRUG Naproxen
  • DRUG ABT-652

Trial Details

FieldValue
Enrollment Target 322 participants
Start Date 2010-09
Est. Completion 2011-05
Phase Phase 2

Sponsor

AbbVie (prior sponsor, Abbott)

88 total trials

What the Registry Record Tells You About NCT01207115

The ClinicalTrials.gov registry entry for NCT01207115 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 322 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01207115 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01207115 about?

NCT01207115 is a clinical study titled "A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee". To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.

What is the current status of trial NCT01207115?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 322 participants. The study started on 2010-09. Estimated completion is 2011-05.

What interventions are being tested in trial NCT01207115?

The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), ABT-652 (DRUG).

Who is sponsoring clinical trial NCT01207115?

This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.